Yahoo Finance

Inflammasome Therapeutics to Collaborate with Sean M. Healey & AMG Center for ALS on a new treatment for Amyotrophic Lateral Sclerosis (ALS)

NEWTON, Mass., November 13, 2025--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and ...

AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS

PRESS RELEASEAB SCIENCE IS INVITED TO PRESENT AT THE 2026 ENCALS ANNUAL MEETING THE SURVIVAL DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC ...
Nasdaq

Voyager Provides Update on SOD1 ALS Gene Therapy Program

LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...
EurekAlert!

Cedars-Sinai certified by ALS Association as Center of Excellence for treatment, research

LOS ANGELES (Sept. 30, 2014) – The ALS Program at Cedars-Sinai has become the first in Southern California to be named an ALS Association Certified Treatment Center of Excellence – a distinction that ...
Yahoo Finance

New Data from the NIH-Funded CNM-Au8® Expanded Access Program Provides Support for a Survival Benefit in ALS

WASHINGTON, Dec. 4, 2025 /PRNewswire/ -- I AM ALS celebrates promising new analyses released by Clene Nanomedicine demonstrating significant improvements in survival associated with their treatment, ...

ALS Canada rallies around progress in research and a call for continued action this ALS Awareness Month

This ALS Awareness Month, the ALS Society of Canada (ALS Canada) recognizes meaningful progress in amyotrophic lateral ...
Nasdaq

Clene to Provide CNM-Au8® ALS Program Update

SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage ...